Skip to main content

Dogwood Therapeutics, Inc. (DWTX)

New York Stock Exchange Healthcare BiotechnologyView data quality →
38.8Poor

ValueMarkers Composite Index

Top 5%#42,543 of 44,707
Overvalued

187% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
-2.48
Distress
DCF Value
$1
Overvalued
ROIC
-32.1%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Dogwood Therapeutics, Inc. (DWTX) — VMCI valuation read

Across 120 indicators, Dogwood Therapeutics, Inc. (DWTX) lands at VMCI 39/100. The Healthcare sector median is 50, so the 11-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on DWTX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, DWTX trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -0.6x leaves covenant headroom for DWTX on the trailing balance sheet.

DWTX fell 2.0% over the trailing 7 days, with a -4.0% read on a 30-day basis.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

CEO: Gregory Duncan12 employeesUSwww.dwtx.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in DWTX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.